JPMORGAN CHASE & CO - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 316 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$120,836,723
-4.1%
3,163,265
-9.5%
0.01%
-7.1%
Q2 2023$126,068,077
-6.3%
3,495,095
-0.8%
0.01%
-12.5%
Q1 2023$134,535,323
+73152.4%
3,522,776
+9.1%
0.02%
-33.3%
Q4 2022$183,660
-99.9%
3,227,777
-17.9%
0.02%
+9.1%
Q3 2022$155,511,000
-13.6%
3,933,026
-3.8%
0.02%
-12.0%
Q2 2022$179,900,000
-10.5%
4,088,642
-18.9%
0.02%
+4.2%
Q1 2022$200,986,000
-2.5%
5,039,771
-1.7%
0.02%0.0%
Q4 2021$206,129,000
-3.7%
5,126,301
-2.6%
0.02%
-7.7%
Q3 2021$214,158,000
-10.3%
5,264,439
+0.2%
0.03%
-7.1%
Q2 2021$238,640,000
+11.8%
5,255,208
+2.7%
0.03%0.0%
Q1 2021$213,415,000
-4.0%
5,119,082
-1.6%
0.03%
-15.2%
Q4 2020$222,202,000
+68.6%
5,202,572
+4.7%
0.03%
+50.0%
Q3 2020$131,760,000
-1.0%
4,970,189
+0.1%
0.02%
-15.4%
Q2 2020$133,088,000
+52.0%
4,964,144
+2.0%
0.03%
+23.8%
Q1 2020$87,573,000
+7.3%
4,867,887
+5.7%
0.02%
+40.0%
Q4 2019$81,627,000
+4.7%
4,603,933
-8.4%
0.02%
-6.2%
Q3 2019$77,933,000
-4.1%
5,024,697
+4.2%
0.02%0.0%
Q2 2019$81,269,000
+15.0%
4,823,062
+9.9%
0.02%
+14.3%
Q1 2019$70,668,000
+16.6%
4,389,285
+6.0%
0.01%0.0%
Q4 2018$60,591,000
-7.4%
4,141,515
+15.0%
0.01%
+7.7%
Q3 2018$65,441,000
+21.2%
3,601,604
+12.5%
0.01%
+18.2%
Q2 2018$54,011,000
-11.8%
3,201,596
+2.4%
0.01%
-15.4%
Q1 2018$61,221,000
-4.7%
3,125,123
-1.4%
0.01%
-7.1%
Q4 2017$64,229,000
+28.7%
3,170,207
+10.5%
0.01%
+27.3%
Q3 2017$49,915,000
+45.4%
2,868,670
+7.2%
0.01%
+37.5%
Q2 2017$34,322,000
-9.2%
2,677,194
-8.2%
0.01%
-11.1%
Q1 2017$37,784,000
+39.2%
2,915,415
+6.1%
0.01%
+28.6%
Q4 2016$27,142,000
-24.6%
2,747,066
-7.8%
0.01%
-22.2%
Q3 2016$36,006,000
+35.4%
2,980,634
-3.3%
0.01%
+28.6%
Q2 2016$26,600,000
-9.4%
3,082,218
-0.6%
0.01%
-12.5%
Q1 2016$29,353,000
-10.3%
3,099,576
+64.1%
0.01%0.0%
Q4 2015$32,729,000
+20.8%
1,888,493
-6.4%
0.01%
+14.3%
Q3 2015$27,088,000
-27.3%
2,016,926
+22.3%
0.01%
-22.2%
Q2 2015$37,251,000
+56.0%
1,649,750
-1.3%
0.01%
+80.0%
Q1 2015$23,874,000
+37.8%
1,671,867
-6.9%
0.01%
+25.0%
Q4 2014$17,329,000
-0.7%
1,795,732
-6.4%
0.00%0.0%
Q3 2014$17,452,000
-9.0%
1,917,792
-1.2%
0.00%
-20.0%
Q2 2014$19,181,000
-9.3%
1,941,445
+16.7%
0.01%
-16.7%
Q1 2014$21,143,000
-32.3%
1,664,033
-20.1%
0.01%
-33.3%
Q4 2013$31,218,000
+35.2%
2,082,591
-0.4%
0.01%
+28.6%
Q3 2013$23,088,000
+30.6%
2,091,463
-6.0%
0.01%
+16.7%
Q2 2013$17,684,0002,224,3110.01%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
SNYDER CAPITAL MANAGEMENT L P 4,324,232$165,185,6623.73%
Steamboat Capital Partners, LLC 196,898$7,521,5042.79%
2Xideas AG 600,799$22,950,5222.54%
BERNZOTT CAPITAL ADVISORS 171,808$6,563,0662.26%
Redwood Investments, LLC 328,459$12,547,1341.70%
Mesirow Institutional Investment Management, Inc. 380,415$14,531,8531.47%
Granite Investment Partners, LLC 856,253$32,708,8651.37%
Penn Capital Management Company, LLC 324,707$12,453,2111.28%
EFG Asset Management (North America) Corp. 137,739$5,262,3191.25%
First Light Asset Management, LLC 313,536$11,977,0751.14%
View complete list of HALOZYME THERAPEUTICS INC shareholders